|
Dr. W.
Roy Smythe |
Dr. Smythe is involved in the surgical
diagnosis and treatment of mesothelioma patients. He has designed a pilot protocol at M.
D. Anderson for malignant pleural mesothelioma involving aggressive surgical therapy
followed by intensity modulated radiation therapy (IMRT). In the laboratory, he was
involved in the initial research work evaluating gene therapy for this disease in the mid
1990's at the University of Pennsylvania. He is currently evaluating a number of novel
gene therapy and molecular approaches to the treatment of this disease, and hopes to bring
one or more of these to the clinic in the next year. W. Roy Smythe, MD
Assistant Professor of Surgery
Department of Thoracic and Cardiovascular Surgery
Section of Thoracic Molecular Oncology
The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Houston, Texas
|
An Update -- 10/16/01
I have a couple of updates for you on recent meso events
here at Anderson - we are rapidly removing the inertia for treatment and research that
existed here when I arrived 3 years ago.
(1)
Our EPP followed by IMRT
phase I/II trial has passed the IRB, and we are beginning to enter patients - in what
format do you want the information for the MARF website? Still no local recurrences in the
pilot group, most with stage III disease!
(2) I have formed a multidisciplinary Mesothelioma Working Group here at Anderson - we
are working on the followingparticipation in the UChi/NCI phase II bevacizumab trial, the
development of one or two of our own non-surgical phase I biologic treatment trials - in
the works, a frozen tumor bank to correlate with our prospective patient database in the
CT surgery department, and a program project NIH grant.
(3)
We have contracted with
the international journal Lung Cancerto provide a clinicopathologic case review every
other month for publication from MDACC - we are planning sarcomatous meso to be the 2nd
topic submitted.
(4)
My laboratory work
continues to go well, we are taking 4 candidate molecular therapies which look good in
vitro into animal models this fall.
Dr. W. Roy Smythe
- RESIDENCY
General Surgery 1989-1996
Hospital of The University of Pennsylvania
Children's Hospital of Philadelphia
Thoracic and Cardiovascular Surgery 1996-1998
Hospital of The University of Pennsylvania
Children's Hospital of Philadelphia
- POSTDOCTORAL RESEARCH
The Harrison Department of Surgical Research 1993-1996
Thoracic Oncology and Gene Therapy
The University of Pennsylvania College of Medicine
American Cancer Society Clinical Oncology Fellow 1994-1995
Hospital of The University of Pennsylvania
- CURRENT STAFF POSITIONS
Assistant Professor of Surgery and Assistant Surgeon
The University of Texas M. D. Anderson Cancer Center
Department of Thoracic and Cardiovascular Surgery
Institutional Physician-Scientist
The University of Texas M. D. Anderson Cancer Center
The Section of Thoracic Molecular Oncolog
- BOARD CERTIFICATIONS
American Board of Surgery
American Board of Thoracic Surgery
SELECTED MANUSCRIPTS (from a list of 46)
Smythe, W.R., Hwang, H.C., Amin, K.M., Eck, S., Wilson, J.M., Albelda, S.M., and
Kaiser L.R. Recombinant adenovirus transfer of the HSV-thymidine kinase gene to thoracic
neoplasms: an effective in vitro drug sensitization system. Cancer Res., 54:2055-2059,199
Smythe, W.R., Kaiser, L.R., Amin, K.M., Pilewski, J.M., Eck, S., Wilson, J.M,
and Albelda, S.M. Successful adenovirus-mediated gene transfer in an in vivo model of
human malignant mesothelioma. Ann. Thorac. Surg., 57:1395-1401,1994
Smythe, W.R., Hwang, H.C., Elshami, A.A., Amin, K.M., Kaiser, L.R., and Albelda,
S.M. Differential sensitivity of thoracic malignancies to adenovirus-mediated drug
sensitization gene therapy. J. Thorac. Cardiovasc. Surg., 109:626-631, 1994
Smythe, W.R., Hwang, H.C., Amin, K., Wilson, J., Albelda, S.M., Kaiser, and L.R.
Significant survival benefit following adenovirus-mediated gene therapy for experimental
malignant human mesothelioma. Surgical Forum, Volume XLV:499-502,1994.
Amin, K.M., Litzky, L.A., Smythe, W.R., Mooney, A.M., Morris, J.M., Mews,
D.J.D., Pass, H.I., Kair, C., Rodeck, U., Rauscher, F.J., Kaiser, L.R., and Albelda, S.M.
The Wilms tumor-1 susceptibility (WT1) gene and protein are selectively expressed in
malignant mesothelioma. Am. J. Pathol., 146:344-356, 1995.
Smythe, W.R., Hwang, H.C., Elshami, A.A., Amin, K.M., Davidson, B.L., Wilson,
J.M., Kaiser, L.R., and Albelda, S.M. Treatment of experimental human mesothelioma using
adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg., 222(1):78-86,
1995
Hwang, H.C., Smythe, W.R., Elshami, A.A., Kucharczuk, J.C., Amin, K.M.,
Williams, J.L., Litzky, L.A., Kaiser, L.R., and Albelda, S.M. Gene therapy using
adenovirus carrying the herpes simplex-thymidine kinase gene to treat animal models of
human malignant mesothelioma and lung cancer. Am. J. Respir. Cell Mol. Biol., 13:7-16,
1995
Kucharczuk, J.C., Elshami, A.A., Zhang, H.B., Smythe, W.R., Hwang, H.C.,
Tomlinson, J.S., Amin, K.M., Litzky, L.A., Albelda, S.M., and Kaiser, L.R. An intrapleural
model of mesothelioma in an immune competent animal to study gene transfer. Ann. Thorac.
Surg., 60:593-598, 1995
Elshami, A.A., Kucharczuk, J.C., Zhang, H.B., Smythe, W.R., Hwang, H.C., Litzky,
L.A., Kaiser, L.R., and Albelda, S.M. Treatment of pleural mesothelioma in an
immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus
thymidine kinase gene. Hum. Gene Ther., 7:141-148, 1996
Smythe, W.R. Prodrug / Drug Sensitivity Gene Therapy: Current Status. Curr.
Oncol. Rep., 2(1):17-22., 2000 Mohiuddin, I., Cao, X., and Smythe, W.R. Sodium butyrate
markedly augments proapoptotic gene therapy via alterations in bcl-2 family protein
expression. Surgical Forum Volume 51:118-120, 2000
Pataer, A., Smythe, R., Yu, R., Fang, B., McDonnell, T., Roth, J.A., and
Swisher, S.G. Adenoviral mediated bak gene transfer induces apoptosis in mesothelioma cell
lines. J. Thorac. Cardiovasc. Surg., 2000 (in press)
SELECTED PUBLISHED ABSTRACTS (from a list of 50)
Mohuiddin, I.T., Cao, X., and Smythe, W.R. A novel gene therapy system utilizing
an enzyme activated anthracycline prodrug and adenoviral transfer of betaglucuronidase and
bax. International Gene Therapy of Cancer Meeting, San Diego, CA 2000.
Mohiuddin, I., Cao, X., Roth, J., and Smythe, W. PTEN Over-expression in
Mesothelioma Engenders Cellular Death Via AKT Hypophosphorylation. The Society of Surgical
Oncology, 2000.
Smythe, W.R., Cao, X.X., and Mohuiddin, I. Antisense Therapy For Malignant
Mesothelioma Utilizing Antisense Oligonucleotides Targeting The Bclxl Gene Product. The
American Association of Thoracic Surgery 2001
*** POSTED JANUARY 5, 2001 ***
PATIENT PROFILES
